We are an emerging player on the rare kidney diseases market for adults and children, by developing a portfolio of transformative therapeutic solutions

Our lead drug candidate DTR8 is developed for the treatment of Crescentic Glomerulonephritis (CGN), a severe condition with a high rate of therapeutic failure and associated costs.

DTR8 is a First-In-Class Disease-Modifying Drug for CGN. This is a first local, specific and immediate kidney therapy, with a compagnon test, allowing to stop the degradation of the kidney, preserve its function and decrease the number of patients under dialysis.